Non Small Cell Lung Cancer Therapeutics Market: Global Industry Analysis, Prevention, Management and Mechanisms
Non Small Cell Lung Cancer Therapeutics Market: (By Drug Class: Angiogenesis Inhibitor, EGFR Inhibitor, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, and PD-1/PD-L1 Inhibitor): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023 Size and Share Published in 2015-11-27 Available for US$ 5795 at Researchmoz.us
Description
This report on the non-small cell lung cancer (NSCLC) Therapeutics market studies the current and future prospects of the global market. Non-small cell lung cancer is a type of lung cancer which accounted 85-90% of all lung cancers. There are three major subtypes of NSCLC namely squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. NSCLC is relatively insensitive to chemotherapy compared to small cell lung cancer. Increasing awareness along with incidence rate are expected to propel the global non-small cell lung cancer therapeutics market.
The NSCLC market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global NSCLC therapeutics market with respect to the segments based on the type of drug class, and their geographic analysis. A detailed qualitative analysis of driving and restraining factors for the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global NSCLC therapeutics market.
Based on drug class, the NSCLC therapeutics market has been segmented into six major categories: angiogenesis inhibitor, epidermal growth factor receptor blocker, kinase inhibitor, microtubule stabilizer, folate antimetabolites, and PD-1/ PD-L1 inhibitor. The market segments have been extensively analyzed based on usefulness, efficacy, revenue, and geographical coverage. The market size and forecast in terms of USD million for each segment has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year.
Download Sample of this Report at: http://www.researchmoz.us/enquiry.php?type=S&repid=497268
Geographically, the global NSCLC therapeutics market has been categorized into four major regions and the key countries in the respective region: North America (U.S., Canada), Europe (U.K., Germany, Rest of Europe), Asia Pacific (Japan, China, and Rest of Asia Pacific), and Rest of the World. The market size and forecast for each of these regions and the mentioned countries has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions.
The report also profiles major players in the global NSCLC therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include Genentech, Inc. ( a Roche Company), Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Pfizer, Inc., Novartis AG, Astra Zeneca plc, and Celgene Corporation.
The global non-small cell lung cancer therapeutics market is segmented as follows:
Global Non-Small Cell Lung Cancer Therapeutics Market, by Drug Class, 2013–2023 (US$ Mn)
Overview
Angiogenesis Inhibitor
Avastin (bevacizumab)
Cyramza (Ramucirumab)
Epidermal Growth Factor Receptor Blocker
Tarceva (erlotinib)
Gilotrif (afatinib)
Iressa (gefitinib)
Kinase Inhibitor
Xalkori (crizotinib)
Zykadia (ceritinib)
Microtubule Stabilizer
Abraxane (paclitaxel protein bound)
Docetaxel
Folate Antimetabolites
Alimta (pemetrexed)
PD-1/ PD-L1 Inhibitor
Opdivo (nivolumab)
Keytruda (pembrolizumab)
Pipeline Analysis: Global Non-Small Cell Lung Cancer Therapeutics Market
Overview
Late Stage (Phase III) Forecast for Phase III Drugs Post Expected Launch till 2023 (US$ Mn)
Avelumab - Pfizer, Inc.
MPDL3280A - Roche
MEDI4736 - AstraZeneca
Abemaciclib - Eli Lilly and Company
Others
Early Stage (Phase I and II) (Qualitative Analysis - Tabular representation)
Global Non-Small Cell Lung Cancer Therapeutics Market, by Geography, 2013–2023 (US$ Mn)
Overview
North America
U.S.
Canada
Europe
U.K.
Germany
Rest of Europe
Asia Pacific
Japan
China
Rest of Asia Pacific
Rest of the World
Make an Enquiry: http://www.researchmoz.us/enquiry.php?type=E&repid=497268
Table of Content
1. Preface
1.1. Report Description
1.2. Research Methodology
1.3. Market Segmentation
2. Executive Summary
2.1. Market Snapshot
2.2. Comparative Analysis: Non-Small Cell Lung Cancer Market, by Geography, 2014 & 2023 (Value %)
Browse All Pharmaceutical Market Research Reports at: http://www.researchmoz.us/pharmaceutical-market-reports-38.html
About ResearchMoz
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives.
Contact Us:
ResearchMoz
Mr. Nachiket Ghumare, +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
sales@researchmoz.us
http://www.researchmoz.us/